Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

PR Newswire
December 27, 2021 — 18:45 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Beijing biotech Casino China Covid-19 healthcare Hong Kong JD finance Macau medicine taiwan United States Vaccine

Related News:

Pioneering Cutting-Edge Technologies: High-End Medical Imaging Developer VITAL HealthCare Debuts at CMEF

April 13, 2024 — 20:00

Ugreen’s Inaugural Network Attached Storage NASync Series shown at NAB Show 2024

April 13, 2024 — 20:00

IOT Data Hackathon Award Ceremony – Data-driven Economy: Unleashing the Powerhouse of Possibilities

April 13, 2024 — 18:30

Xi Jinping on the Belt and Road Initiative informs and inspires readers in Chile

April 13, 2024 — 18:04

Goldpac Exhibits at InnoEx 2024

April 13, 2024 — 10:00

DJI Presents Best-In-Class Creator Tools at the 2024 NAB Show

April 13, 2024 — 01:00

CJ 4DPLEX and Palace Amusement® to Launch First Ever 4DX Theater in Jamaica

April 12, 2024 — 03:45

Dachser acquires food logistics provider Brummer

April 11, 2024 — 10:00

St. Joseph’s Children’s Hospital Foundation Receives Historic $50 Million Gift from the Pagidipati Family of Tampa

April 11, 2024 — 09:18